CSL LIMITED - Charts / Financials

0.91%

$238.86

Market Cap $115.6B

Healthcare Biotechnology

CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus... CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others. More

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care. WEBINAR: What investors should know about what it takes for ASX-listed companies to get medical developments...

REFRESH

Day
Open	$242.00		Day High	$242.00		Day Low	$237.72
Daily Volume	723664

Bids				Sellers
Number	Price	Volume		Number	Price	Volume
1	$238.86	1620		1	$238.88	1181

Directors & Senior Management

Mr. Paul F. Mckenzie	Chief Executive Officer, Managing Director, Executive Director
Ms. Joy Linton	Chief Financial Officer
Ms. Roanne Parry	Chief Human Resources Officer
Mr. Mark Hill	Executive Vice President, Chief Digital Information Officer
Mr. Greg Boss	Executive Vice President, Legal and CSL Group General Counsel
Mr. Ken Lim	Executive Vice President, Chief Strategy Officer
Dr. William Mezzanotte	Executive Vice President, Head Research & Development
Mr. Andy Schmeltz	Executive Vice President - CSL Behring
Mr. Herve Gisserot	Senior Vice President, General Manager - CSL Vifor
Mr. Stephen Marlow	Senior Vice President, General Manager - CSL Plasma
Dr. Brian Anthony Mcnamee	Non-Executive Independent Chairman of the Board
Dr. Brian Daniels	Non-Executive Director
Dr. Megan Elizabeth Clark	Independent Non-Executive Director
Dr. Robert Andrew Cuthbertson	Non-Executive Independent Director
Ms. Carolyn Judith Hewson	Independent Non-executive Director

Data source: Refinitiv

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $238.86		Change -2.190(0.91%)		Mkt cap ! $115.6B

Open	High	Low	Value	Volume
$242.00	$242.00	$237.72	$176.2M	723.6K

Buyers (Bids)

No.	Vol.	Price($)
1	1620	$238.86

Sellers (Offers)

Price($)	Vol.	No.
$238.88	1181	1

View Market Depth

No.	Vol.	Price($)
1	200	238.200
1	90	238.140
1	100	238.080
1	51	238.050
4	1769	238.000

Price($)	Vol.	No.
239.290	4500	1
239.300	50	1
240.000	136	3
240.500	100	1
240.770	85	1

Last trade - 16.10pm 13/06/2025 (20 minute delay)

CSL (ASX) Chart

CSL LIMITED - Charts / Financials

Directors & Senior Management

Buyers (Bids)

Sellers (Offers)

Top Stories